%PDF-1.4
%
43 0 obj
<>
endobj
39 0 obj
<>
endobj
99 0 obj
<>stream
Acrobat Distiller 5.0 for Macintosh
2002-12-09T23:15:21Z
2024-03-28T11:56:36-07:00
2024-03-28T11:56:36-07:00
QuarkXPress. 4.11: AdobePS 8.7.2 (104)
application/pdf
Heather
2001-896.jan
uuid:959ead2b-1dd1-11b2-0a00-040a278d5b00
uuid:959ead2e-1dd1-11b2-0a00-1e0000000000
endstream
endobj
28 0 obj
<>
endobj
29 0 obj
<>
endobj
44 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
10 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
13 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
16 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
125 0 obj
[129 0 R]
endobj
126 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
/CS0 cs 0 0 0 0 scn
/GS1 gs
440 777 117 -27 re
f
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
0 0 0 1 scn
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2003; 30:1)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(138)Tj
ET
0 0 0 0 scn
/GS0 gs
108.25 59.1 396.47 -10.84 re
f
0.5 w
108.25 59.1 396.47 -10.84 re
S
BT
0 0 0 1 scn
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 74.4 714.5293 Tm
(Prospective Osteoporosis Study \(EPOS\). Osteoporosis Int)Tj
0 Tc 0 Tw 0 -1.25 TD
(1998;8:291-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(44.)-875.1 (Cooper C. )17.7 (The crippling consequences of fractures and their impact)]TJ
0 Tc 2.175 -1.25 Td
[(on quality of life. )54.8 (Am J Med 1997;103 Suppl 2A:12S-10S.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(45.)-875.1 (Spector )17.7 (TD, McCloskey EV)128.8 (, Doyle DV)128.8 (, Kanis JA. Prevalence of)]TJ
2.175 -1.25 Td
(vertebral fracture in women and the relationship with bone density)Tj
T*
[(and symptoms: )17.7 (The Chingford Study)64.8 (. J Bone Miner Res)]TJ
0 Tc 0 Tw T*
(1993;8:817-22.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(46.)-875.1 (Cook DJ, Guyatt GH, )54.8 (Adachi JD, et al. Quality of life issues in)]TJ
2.175 -1.25 Td
[(women with vertebral fractures due to osteoporosis. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1993;36:750-6.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(47.)-875.1 (Gabriel SE, Kneeland )17.7 (TS, Melton LJ, Moncur MM, Ettinger B,)]TJ
0 Tc 0 Tw 2.175 -1.25 Td
(T)Tj
-0.00011 Tc 0.02499 Tw 0.541 0 Td
[(osteson )54.8 (ANA. Health-related quality of life in economic)]TJ
-0.541 -1.25 Td
(evaluations for osteoporosis. Med Decis Making 1999;19:141-4.)Tj
-2.175 -1.25 Td
[(48.)-875.1 (T)69.9 (osteson )54.8 (AN. Quality of life in the economic evaluation of)]TJ
2.175 -1.25 Td
(osteoporosis prevention and treatment. Spine 1997;22 Suppl)Tj
0 Tw T*
(24:58S-62S.)Tj
0.02499 Tw -2.175 -1.25 Td
[(49.)-875.1 (Dere )17.7 (W)91.9 (,)-0.1 ( )54.8 (A)74 (vouac B, Boers M, et al. Recommendations for the health)]TJ
2.175 -1.25 Td
(economics analysis to be performed with a drug to be registered in)Tj
T*
[(prevention or treatment of osteoporosis. Calcif )17.7 (T)35 (issue Int)]TJ
0 Tc 0 Tw T*
(1998;63:93-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(50.)-875.1 (Bone HG, Greenspan SL, McKeever C, et al. )54.8 (Alendronate and)]TJ
2.175 -1.25 Td
[(estrogen ef)17.7 (fects in postmenopausal women with low bone mineral)]TJ
T*
[(density)64.8 (. J Clin Endocrinol Metab 2000;85:727-33.)]TJ
-2.175 -1.25 Td
[(51.)-875.1 (Nashel DJ. Is atherosclerosis a complication of long-term)]TJ
2.175 -1.25 Td
[(corticosteroid treatment. )54.8 (Am J Med 1986;80:925-9.)]TJ
30.825 31.25 Td
[(52.)-875.1 (Black DM, Sarkar S, Mitlak B, Knickerbocker R, Cummings SR.)]TJ
2.175 -1.25 Td
[(What proportion of the ef)17.7 (fects of raloxifene \(RLX\) on vertebral)]TJ
T*
(fracture risk can be directly attributed to its bone mineral density)Tj
T*
[(\(BMD\) ef)17.7 (fects? J Bone Miner Res 1999;14 Suppl 1:S158.)]TJ
-2.175 -1.25 Td
[(53.)-875.1 (Black DM, Pearson J, Harris F)79.7 (, LaCroix )54.8 (A, Cummings SR.)]TJ
2.175 -1.25 Td
[(Predicting the ef)17.7 (fect of antiresorptive treatment on risk of vertebral)]TJ
T*
[(fractures: )54.8 (A)-220.1 (meta-analysis. J Bone Miner Res 1999;14 Suppl)]TJ
0 Tc 0 Tw T*
(1:S137.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(54.)-875.1 (Ensrud KE, Nevitt MC, Palermo L, Cauley JA, Grif)17.7 (fith JM, Genant)]TJ
2.175 -1.25 Td
[(HK, Black DM. )17.7 (What proportion of incident morphometric)]TJ
T*
(vertebral fractures are clinically diagnosed and vice versa? J Bone)Tj
T*
(Miner Res 1999;14 Suppl 1:S138.)Tj
-2.175 -1.25 Td
[(55.)-875.1 (Buckley LM, Marquez M, Hudson JO, et al. )17.7 (V)110.8 (ariations in)]TJ
2.175 -1.25 Td
[(physicians\325)-201.1 (judgments about corticosteroid-induced osteoporosis by)]TJ
T*
[(physician specialty)64.8 (. J Rheumatol 1998;25:2195-202.)]TJ
-2.175 -1.25 Td
[(56.)-875.1 (W)79.9 (alsh LJ, )17.7 (W)79.9 (ong CA, Pringle M, )17.7 (T)69.9 (a)0.1 (ttersfield )54.8 (AE. Use of oral)]TJ
2.175 -1.25 Td
(corticosteroids in the community and the prevention of secondary)Tj
T*
[(osteoporosis: a cross sectional study)64.8 (. BMJ 1996;313:344-6.)]TJ
-2.175 -1.25 Td
[(57.)-875.1 (Buckley LM, Marquez M, Freezor R, Ruf)17.7 (fin DM, Benson LL.)]TJ
2.175 -1.25 Td
[(Prevention of corticosteroid-induced osteoporosis. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1999;42:1736-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(58.)-875.1 (Aagaard EM, Lin P)110.7 (,)-0.1 ( Modin GW)91.7 (, Lane NE. Prevention of)]TJ
2.175 -1.25 Td
(glucocorticoid-induced osteoporosis: provider practice at an urban)Tj
0 Tc T*
[(county hospital. )54.8 (Am J Med 1999;107:456-60.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(59.)-875.1 (Mudano )54.8 (A, )54.8 (Allison J, Hill J, Rothermel )17.7 (T)74 (,)-0.1 ( Saag K. )17.7 (V)110.8 (ariations in)]TJ
2.175 -1.25 Td
(glucocorticoid osteoporosis in a managed care cohort. J Rheumatol)Tj
0 Tc 0 Tw T*
(2001;28:1298-305.)Tj
ET
0 0 0 0 scn
438 770 120 -25 re
f
BT
0 0 0 1 scn
/T1_2 1 Tf
-0.00011 Tc 20.37 0 0 21 439 753.6089 Tm
(2001-896-7)Tj
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
47 0 obj
<>
endobj
56 0 obj
<>
endobj
48 0 obj
<>
endobj
84 0 obj
<>
endobj
104 0 obj
<>
endobj
50 0 obj
<>
endobj
52 0 obj
<>
endobj
49 0 obj
<>stream
HTMO0>8)ei>.qG%Fiwؿǎkq[WF".)ZGynN;4%ˊ3;=.k N!|~JoOt/gK-Lu`ڇлo`$2(S'L-fBQw̳_!5܆J(J)k"F>Ǫ%WePWR:DL=6M
73Q ppm@4ȗy<)FZBZl5Oyx}?#
endstream
endobj
51 0 obj
<>stream
H\S{PSw *>jhrozEdkʣQ<ፈQ^5$